Mixed
Nabiximols: improve symptoms or function in MS (type not specified)
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
MS (type not specified) · Spasticity
Controlled trials disagree.
- Trials
- 13
- Running now
- 0
- Controlled phase 2/3 trials
- 12
- People in controlled trials
- 2007
Deciding trials (phase 3): 2 met, 3 did not.
Other linked trials: 8
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2021 · Placebo-controlled · MSFT-NCT04984278
Phase 3 · 2020 · Placebo-controlled · MSFT-NCT04657666
Phase 3 · 2020 · Placebo-controlled · MSFT-NCT04203498
- A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)decides the statusMet main goal
Phase 3 · 2008 · Placebo-controlled · MSFT-NCT00681538
- Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosisdecides the statusMet main goal
Phase 3 · 2007 · Placebo-controlled · MSFT-NCT00702468
- Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MSdecides the statusMissed main goal
Phase 3 · 2006 · Placebo-controlled · MSFT-NCT00391079
Phase 3 · 2005 · Placebo-controlled · MSFT-NCT01599234
- A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosisdecides the statusMissed main goal
Phase 3 · 2002 · Placebo-controlled · MSFT-NCT00678795
- A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.decides the statusMet main goal
Phase 3 · 2002 · Placebo-controlled · MSFT-NCT00711646
- A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origindecides the statusMissed main goal
Phase 3 · 2002 · Placebo-controlled · MSFT-NCT01606176
Other linked trials: 8
These linked trials do not set the status.
- A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis PatientsNo result found
Phase 4 · 2012 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28First listed as Mixed
Related hypotheses
- Spasticity: improve symptoms or function in MS (type not specified)
- Arbaclofen: improve symptoms or function in MS (type not specified)
- Baclofen: improve symptoms or function in MS (type not specified)
- Botulinum toxin type a: improve symptoms or function in MS (type not specified)
- Cannabidiol: improve symptoms or function in MS (type not specified)
- Dronabinol: improve symptoms or function in MS (type not specified)
- Nabilone: improve symptoms or function in MS (type not specified)
- Nabiximols: improve symptoms or function in NMOSD
- Nabiximols: improve symptoms or function in relapsing MS
- Nabiximols: improve symptoms or function in relapsing and progressive MS
- Onabotulinumtoxina: improve symptoms or function in MS (type not specified)
- Rimabotulinumtoxinb: improve symptoms or function in MS (type not specified)
- Tizanidine: improve symptoms or function in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error